Prodigiosin/灵菌红素的PubChem识别号5351169

Prodigiosin/灵菌红素的PubChem识别号5351169

灵菌红素         CAS 号. 82-89-3

灵菌红素是由若干种细菌特别是粘质沙雷菌产生的一种红色吡咯色素。灵菌红素有广谱的生物学活性，抗真菌、肿瘤细胞系和疟疾。2007年发现它是一种免疫抑制剂。近来灵菌红素的作用方式受到大量的关注，作为一种诱导剂通过活化半胱天冬酶诱导人原发性癌细胞的凋亡，并通过转化β生长因子受体途径诱导p21WAF1/CIP1表达，通过作用3β糖原合成酶激酶活化N-乙酰-β-葡萄糖苷酶。

Prodigiosin  

Prodigiosin is an intensely red pyrrole pigment produced by several bacteria, most notably, Serratia marcescens. Prodigiosin has a broad biological profile with activity against fungi, tumor cell lines and malaria. It was shown to be an immunosuppressant in 2007. The mode of action of prodigiosin has recently received considerable attention as an inducer of apoptosis in human primary cancer cells via caspase activation. Prodigiosin also acts as an inducer of p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway, and of NAG-1activation by acting on glycogen synthase kinase-3beta.

CAS # : 82-89-3
Molecular Formula : C20H25N3O
Molecular Weight : 323.4
Source : Serratia marcescens MST-AS5330
Appearance : Dark red solid
Purity : > 95%
Long Term Storage : -20°C
Solubility : Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility

References
1. Seeing red: The story of prodigiosin. Bennett J.W. & Bentley R., Adv. Appl. Microbiol. 2000, 47, 1.
2. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Campas C. et
al., Leukemia 2003, 17, 746.
3. Prodigiosin: a novel family of immunosuppressants with anti-cancer activity. Pandey R. et al., Indian J.
Biochem. Biophys. 2007, 44, 295.
4. The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factorbeta
receptor pathway. Soto-Cerrato V. et al., Biochem Pharmacol. 2007, 74, 1340.
5. Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human
breast cancer cells. Soto-Cerrato V. et al., Mol. Cancer Ther. 2007, 6, 362.
6. Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7
MR) cell line. Monge M. et al., Invest. New Drugs 2007, 25, 21.